Current state of systemic therapy of metastatic renal cell carcinoma;Aktuelles zur Systemtherapie des metastasierten Nierenzellkarzinoms

Urologe - Ausgabe A

Volumn 48, Issue 9, 2009, Pages 983-989

  Merseburger, A S ^a   Waalkes, S ^a   Kuczyk, M A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Metastases; Prognosis; Renal cell carcinoma; Targeted therapy

Indexed keywords

AFINITOR; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER THERAPY; CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; METASTASIS; NEPHRECTOMY; PROGNOSIS; REVIEW; SYSTEMIC THERAPY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS;

EID: 70349244672     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-009-2072-7     Document Type: Review

References (31)

1. Merseburger AS, Kuczyk MA (2008) Value of targeted therapies for renal cell cancer. Urologe A 47:1303-1310
2. Staehler M, Haseke N, Zilinberg K et al (2008) Systemic therapy of metastasizing renal cell carcinoma. Urologe A 47:1357-1367
3. Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540
4. Miller K, Bergmann L, Albers P et al (2007) Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma. Aktuel Urol 38:328-330
5. Motzer RJ, Hutson TE, Tomczak P et al (2007) Suni-tinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
6. Figlin RA, Hutson TE, Tomczak P et al (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26:5024
7. Johannsen M, Florcken A, Bex A et al (2008) Can Tyrosine Kinase inhibitors be discontinued in patients with metastatic Renal Cell Carcinoma and a complete response to treatment? A Multicentre, Retrospective Analysis. Eur Urol 53:917-930
8. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111
9. Escudier BJ, Bellmunt J, Negrier S et al (2009) Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-{alpha}2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27:5020
10. Rini BI, Halabi S, Rosenberg JE et al (2009) Bevacizumab plus interferon alfa versus interferon al-fa monotherapy in patients with metastatic Renal Cell Carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 27(Suppl 2): 235-241
11. Hudes G, Carducci M, Tomczak P et al (2007) Tem-sirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281 (Pubitemid 46849157)
12. Escudier B, EisenT, Stadler WM et al (2007) Sorafe-nib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
13. Amato RJ, Jac J, Harris P et al (2008) A phase II trial of intra-patient dose escalated-sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 26:5122
14. Kay RM A, Figlin R, Escudier B et al (2009) Updated data from a phase III randomized trial of evero-limus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15):5032
15. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
16. Dudek AZ, Zolnierek J, Dham A et al (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:61-67
17. Eichelberg C, Heuer R, Chun FK et al (2008) Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54:1373-1378
18. Herrmann E, BiererS, Gerss J et al (2008) Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients. Oncology 74:216-222
19. Porta CPG, Sabbatini R, Bearz A et al (2008) Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur Urol 252(Suppl)
20. Sablin MP, Negrier S, Ravaud A et al (2009) Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182:29-34
21. Tamaskar I, Garcia JA, Elson P et al (2008) Antitu-mor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179:81-86
22. Zimmermann K, Schmittel A, Steiner U et al (2009) Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76:350-354
23. Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659
24. Mickisch GH, Garin A, van Poppel H et al (2001) Radical nephrectomy plus interferon-alfa-based im-munotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966-970
25. Flanigan RC, Mickisch G, Sylvester R et al (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071-1076
26. Szczylik C, Porta C, Bracarda S et al (2008) Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26:5124
27. Merseburger AS, Kramer MW, Hennenlotter J et al (2008) Loss of galectin-3 expression correlates with clear cell renal carcinoma progression and reduced survival. World J Urol 26:637-642
28. Bui MH, Seligson D, Han KR et al (2003) Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9:802-811
29. Atkins M, Regan M, McDermott D et al (2005) Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714-3721
30. Sternberg CN, Szczylik C, Lee E et al (2009) A randomized, double-blind phase III study of pazopa-nib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 27:5021
31. Rixe O, Bukowski RM, Michaelson MD et al (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8:975-984